Hepatotoxicity associated with low-dose, long-term methotrexate treatment of rheumatoid arthritis

Scand J Rheumatol. 1987;16(4):229-34. doi: 10.3109/03009748709102922.

Abstract

Liver biopsies were performed in 17 patients with therapy-refractory rheumatoid arthritis who were treated successfully with 5-15 mg/week methotrexate (mtx). The average duration of exposure to mtx therapy for each patient was 2.8 years (range 1.5-5 years). Total cumulative mtx doses ranged between 633 and 1,655 mg (mean 1,060 mg). The biopsies revealed 16 cases of normal histology, of which 3 showed nuclear variability in the hepatocytes; 4 with mild fatty infiltration, 2 with mild fatty infiltration and portal round cell infiltration. Portal fibrosis was found in one patient who had psoriasis in addition to clinical RA.

MeSH terms

  • Adult
  • Aged
  • Arthritis, Rheumatoid / drug therapy*
  • Biopsy
  • Chemical and Drug Induced Liver Injury*
  • Fatty Liver / chemically induced
  • Fatty Liver / pathology
  • Female
  • Humans
  • Liver / drug effects
  • Liver / pathology
  • Liver Diseases / pathology
  • Liver Function Tests
  • Male
  • Methotrexate / adverse effects*
  • Methotrexate / therapeutic use
  • Middle Aged
  • Time Factors

Substances

  • Methotrexate